WallStreetZenWallStreetZen

NASDAQ: ANTX
An2 Therapeutics Inc Stock Ownership - Who owns An2 Therapeutics?

Insider buying vs selling

Have An2 Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Joseph S. ZakrzewskiDirector2024-01-18100,000$19.11
$1.91MSell
Adjuvant Global Health Technology Fund LP10% Owner2024-01-1615,907$19.65
$312.57kSell
Kabeer AzizDirector2024-01-1615,907$19.65
$312.57kSell
Kabeer AzizDirector2024-01-1684,093$19.65
$1.65MSell
Adjuvant Global Health Technology Fund LP10% Owner2024-01-1684,093$19.65
$1.65MSell
Robin Shane ReadnourDirector2024-01-12706$21.92
$15.48kSell
Robin Shane ReadnourDirector2024-01-12719$21.91
$15.75kSell
Robin Shane ReadnourDirector2024-01-101,800$21.92
$39.46kSell
Robin Shane ReadnourDirector2024-01-101,869$21.93
$40.99kSell
Kevin Michael KrauseChief Strategy Officer2024-01-095,000$6.60
$33.00kBuy

1 of 6

ANTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ANTX insiders and whales buy or sell their stock.

ANTX Shareholders

What type of owners hold An2 Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Ra Capital Management LP18.67%5,551,295$17.88MInstitution
Adjuvant Global Health Technology Fund LP16.79%4,994,638$16.08MInsider
Kabeer Aziz16.30%4,847,000$15.61MInsider
Ra Capital Management LP14.09%4,189,129$13.49MInsider
Tcg Crossover Management LLC9.00%2,678,209$8.62MInstitution
Bvf Inc5.26%1,563,963$5.04MInstitution
Citadel Advisors LLC5.23%1,556,842$5.01MInstitution
Eric Easom5.02%1,492,301$4.81MInsider
Frazier Life Sciences Management LP4.67%1,388,889$4.47MInstitution
Janus Henderson Group PLC4.30%1,279,975$4.12MInstitution

1 of 3

ANTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ANTX54.22%45.78%Net BuyingNet Selling
CNTB12.93%0.00%
CVM12.96%43.80%Net Buying
MIST33.44%24.16%
CMRX45.42%31.91%Net BuyingNet Selling

An2 Therapeutics Stock Ownership FAQ

Who owns An2 Therapeutics?

An2 Therapeutics (NASDAQ: ANTX) is owned by 68.56% institutional shareholders, 57.88% An2 Therapeutics insiders, and 0.00% retail investors. Adjuvant Global Health Technology Fund LP is the largest individual An2 Therapeutics shareholder, owning 4.99M shares representing 16.79% of the company. Adjuvant Global Health Technology Fund LP's An2 Therapeutics shares are currently valued at $16.23M.

If you're new to stock investing, here's how to buy An2 Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.